Last Updated: May 23, 2026

Claims for Patent: 3,987,200

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 3,987,200

Title:	Method for increasing cardiac contractility
Abstract:	N-Mono or dihydroxyphenylalkyl dopamine derivatives and salts thereof are inotropic agents useful in a method for treatment of acutely depressed cardiac insufficiency.
Inventor(s):	Ronald R. Tuttle, Jack Mills
Assignee:	Eli Lilly and Co
Application Number:	US05/541,179
Patent Claims:	1. The method for increasing cardiac contractility in a warm-blooded mammal suffering from acutely depressed cardiac contractility which comprises administering to said mammal at a rate of between 0.5 and 10 micrograms per kilogram of body weight per minute a compound of the formula ##SPC5##wherein R and R1 are hydrogen or methyl; R2 and R3 are hydrogen or hydroxy, at least one of R2 and R3 being hydroxy; n is 1 or 2;subject to the limitation that when n is 2, R2 is hydrogen and R3 is hydroxy, one of R or R1 is hydrogen and the other is methyl; and the pharmaceutically acceptable acid addition salts thereof with mineral acids. 2. The method of claim 1 wherein the compound administered is a compound of the formula ##SPC6##wherein R and R1 are hydrogen or methyl; R2 and R3 are hydrogen or hydroxy, at least one of R2 and R3 being hydroxy; n is 1 or 2;subject to the limitation that when n is 2, R2 is hydrogen and R3 is hydroxy, one of R or R1 is hydrogen and the other is methyl; with the further limitations that when n is 2 and R2 and R3 are both hydroxy, then R1 is hydrogen, and when n is 1, R2 is hydrogen and R3 is hydroxy, then R and R1 are both hydrogen; and the pharmaceutically acceptable acid addition salts with mineral acids. 3. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-β-phenethylamine hydrochloride. 4. The method of claim 2 wherein the compound administered is levo-3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-β-phenethylamine hydrochloride. 5. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3-hydroxyphenyl-n-propyl]-β-phenethylamine hydrochloride. 6. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-n-propyl]-α-methyl-β-phenethylamine hydrochloride. 7. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[2-(3,4-dihydroxyphenyl)ethyl]-β-phenethylamine. 8. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3,4-dihydroxyphenyl)-n-propyl]-β-phenethylamine hydrochloride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.